Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Declines By 16.6%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 6,170,000 shares, a decline of 16.6% from the January 31st total of 7,400,000 shares. Based on an average daily volume of 905,000 shares, the short-interest ratio is presently 6.8 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth about $108,000. Privium Fund Management B.V. grew its stake in 4D Molecular Therapeutics by 146.3% during the third quarter. Privium Fund Management B.V. now owns 98,500 shares of the company’s stock worth $1,065,000 after buying an additional 58,500 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter worth approximately $295,000. Intech Investment Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter worth approximately $268,000. Finally, Algert Global LLC raised its stake in shares of 4D Molecular Therapeutics by 342.7% in the third quarter. Algert Global LLC now owns 73,436 shares of the company’s stock valued at $794,000 after acquiring an additional 56,848 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Trading Up 4.8 %

NASDAQ:FDMT traded up $0.19 during mid-day trading on Wednesday, hitting $4.16. The company’s stock had a trading volume of 731,126 shares, compared to its average volume of 840,162. The company has a market capitalization of $192.31 million, a price-to-earnings ratio of -1.46 and a beta of 2.81. 4D Molecular Therapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $36.25. The stock has a fifty day moving average of $5.15 and a 200-day moving average of $8.40.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

FDMT has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 19th. Bank of America decreased their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday. Leerink Partners decreased their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Finally, Chardan Capital lowered their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $31.38.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.